Company intelligence / Profile preview

Xell

Bielefeld, North Rhine-Westphalia, Germany

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Xell AG is a globally active supplier of custom and off-the-shelf cell culture media and feeds, particularly for viral vector manufacturing in gene therapy and vaccines; acquired by Sartorius Stedim Biotech in 2021 for €50M plus earn-outs.

Modalities: BiologicsProteinsVaccineMammalian cell culture media
Industry: Chemicals & Materials

Partnerships

BeiGeneBoehringer IngelheimSanofi

Beyond the preview

Go deeper on Xell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xell.

Explore the full profile